Overview

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To investigate the safety, tolerance, pharmacokinetics and pharmacodynamics of tolvaptan 15, 30 and 60 mg after single oral administration in healthy Korean male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Treatments:
Tolvaptan